Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for ACAD, EBS and ATER: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Sunday, 13 June 2021 10:15 AM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / June 13, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ACAD Shareholders Click Here: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16829&wire=1
EBS Shareholders Click Here: https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16829&wire=1
ATER Shareholders Click Here: https://www.zlk.com/pslra-1/aterian-inc-loss-submission-form?prid=16829&wire=1
 

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Sunday, June 13, 2021, Press release picture

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)

ACAD Lawsuit on behalf of: investors who purchased June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline : June 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16829&wire=1

According to the filed complaint, during the class period, Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times

Emergent Biosolutions Inc. (NYSE:EBS)

EBS Lawsuit on behalf of: investors who purchased April 24, 2020 - April 16, 2021
Lead Plaintiff Deadline : June 18, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/emergent-biosolutions-inc-loss-submission-form?prid=16829&wire=1

According to the filed complaint, during the class period, Emergent Biosolutions Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Emergent's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (ii) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (iii) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (iv) as a result of the foregoing, Defendants' public statements about Emergent's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis.

Aterian, Inc. (NASDAQ:ATER)

ATER Lawsuit on behalf of: investors who purchased December 1, 2020 - May 3, 2021
Lead Plaintiff Deadline : July 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/aterian-inc-loss-submission-form?prid=16829&wire=1

According to the filed complaint, during the class period, Aterian, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: